∙ Part A:

• Male participants aged 18 to 55 years, inclusive.

• Body mass index between 18 and 30 kilograms per meter square (kg/m\^2), inclusive, and weighs greater than or equal to (\>=) 50 kilograms (kg), less than or equal to (\<=) 90 kg.

• No clinically significant findings on medical examination, including physical examination, 12-lead electrocardiogram, and clinical laboratory tests.

• Sexually active men must commit to use an effective method of birth control while taking the study intervention and for 90 days after the dose of study intervention.

∙ Part B:

• Male and female participants (only female participants with congenital FVII deficiency) aged 18 to 60 years, inclusive.

• Participants must have one of the following bleeding disorders: Severe hemophilia A (\<1% Factor VIII \[FVIII\]); or Severe and/or moderately severe Hemophilia B (≤ 2% Factor IX \[FIX\]); or Severe FVII deficiency (\<10% FVII activity). Participants with severe FVII deficiency must satisfy with either of following criteria:

‣ Participants with history of \>2 bleeding events in the last 12 months require on-demand treatment with recombinant factor VIIa (rFVIIa) or plasma-derived FVII concentrates (pd-FVII) or fresh frozen plasma (FFP) for bleeding control.

⁃ Participants on prophylaxis treatment with rFVIIa or pd-FVII or FFP regardless of bleeding history.

• Participants with Hemophilia A or Hemophilia B must satisfy either of the following criteria:

‣ Participants not on prophylaxis must have a documented ABR of 6 in 12 months before screening.

⁃ Participants on prophylaxis must have a documented ABR of ≥ 2 in 12 months before screening.

⁃ Intolerant to current treatment regimen.

• Medical records documenting a minimum of 2 years of bleeding event history.

• Willing to undergo a weaning period from prior treatment or prophylaxis for Hemophilia A or Hemophilia B or FVII deficiency.

• Sexually active men must commit to use an effective method of birth control while taking the study intervention and for 90 days after the dose of SR604.

• Women of childbearing potential must have a negative pregnancy test at the Screening Visit and agree to follow the contraception guidance during the intervention period and for at least 90 days after the last dose of SR604.